Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024.

Ms. Nassif is an accomplished biopharmaceutical executive with 25 years of experience, including leading commercial teams to blockbuster status for Pfizer, Novartis Oncology, Merck & Company, and Bristol Myers Squibb.